BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned an average rating of “Moderate Buy” from the twenty-five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seventeen have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $90.0417.

A number of equities analysts have recently commented on BMRN shares. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Canaccord Genuity Group upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and lifted their target price for the company from $84.00 to $98.00 in a research report on Tuesday. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Truist Financial raised their price target on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Finally, Tudor Pickering set a $88.00 price target on shares of BioMarin Pharmaceutical in a report on Monday, November 3rd.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Dodge & Cox boosted its stake in shares of BioMarin Pharmaceutical by 1.0% during the second quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock valued at $830,504,000 after purchasing an additional 153,070 shares in the last quarter. Viking Global Investors LP raised its holdings in BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after buying an additional 1,488,552 shares during the last quarter. AQR Capital Management LLC raised its holdings in BioMarin Pharmaceutical by 6.3% in the 3rd quarter. AQR Capital Management LLC now owns 5,932,109 shares of the biotechnology company’s stock valued at $321,283,000 after buying an additional 351,536 shares during the last quarter. Geode Capital Management LLC boosted its position in BioMarin Pharmaceutical by 1.3% during the 2nd quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock worth $190,417,000 after buying an additional 43,185 shares during the period. Finally, Capital Research Global Investors grew its holdings in BioMarin Pharmaceutical by 547.5% during the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock worth $137,436,000 after acquiring an additional 2,145,717 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Trading Down 1.7%

Shares of BioMarin Pharmaceutical stock opened at $56.21 on Friday. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a 12-month low of $50.76 and a 12-month high of $73.51. The company has a market capitalization of $10.80 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 0.63 and a beta of 0.27. The firm’s 50-day moving average price is $56.20 and its two-hundred day moving average price is $56.03.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). The firm had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, analysts forecast that BioMarin Pharmaceutical will post 3.15 earnings per share for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.